- Home
- ALNY vs VMC Comparison
ALNY vs VMC Comparison
Compare ALNY & VMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | VMC |
|---|---|---|
| Founded | 2002 | 1909 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 36.2B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALNY | VMC |
|---|---|---|
| Price | $296.14 | $281.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | ★ $471.00 | $323.17 |
| AVG Volume (30 Days) | 869.5K | ★ 1.1M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | ★ 206.88 | 18.39 |
| EPS | ★ 2.33 | 1.26 |
| Revenue | $1,037,418,000.00 | ★ $7,781,900,000.00 |
| Revenue This Year | $52.67 | $1.85 |
| Revenue Next Year | $31.48 | $6.22 |
| P/E Ratio | ★ $127.76 | $221.43 |
| Revenue Growth | ★ 22.88 | 6.38 |
| 52 Week Low | $283.10 | $252.35 |
| 52 Week High | $495.55 | $331.09 |
Technical Indicators
Market Signals| Indicator | ALNY | VMC |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 51.88 |
| Support Level | $284.69 | $252.39 |
| Resistance Level | $322.26 | $301.17 |
| Average True Range (ATR) | 9.95 | 7.05 |
| MACD | 0.97 | 1.03 |
| Stochastic Oscillator | 57.75 | 73.59 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About VMC Vulcan Materials Company (Holding Company)
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2024, the company had 16.5 billion tons of aggregate reserves.